about
Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapyMelatonin enhances photo-oxidation of 2',7'-dichlorodihydrofluorescein by an antioxidant reaction that renders N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK).Development and validation of a single HPLC method for determination of α-tocopherol in cell culture and in human or mouse biological samples.Proanthocyanidin Characterization and Bioactivity of Extracts from Different Parts of Uncaria tomentosa L. (Cat's Claw).IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer.Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer.Evaluation of the biological effect of Ti generated debris from metal implants: ions and nanoparticles.Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells.Monitoring intracellular melatonin levels in human prostate normal and cancer cells by HPLC.Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells.Melatonin prevents glucocorticoid inhibition of cell proliferation and toxicity in hippocampal cells by reducing glucocorticoid receptor nuclear translocation.Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro.Melatonin uptake in prostate cancer cells: intracellular transport versus simple passive diffusion.Development and validation of new methods for the determination of melatonin and its oxidative metabolites by high performance liquid chromatography and capillary electrophoresis, using multivariate optimization.Manganese superoxide dismutase (SOD2/MnSOD)/catalase and SOD2/GPx1 ratios as biomarkers for tumor progression and metastasis in prostate, colon, and lung cancer.Phenotypic changes caused by melatonin increased sensitivity of prostate cancer cells to cytokine-induced apoptosisMnSOD drives neuroendocrine differentiation, androgen independence, and cell survival in prostate cancer cells
P50
Q24597964-061A4A8D-C88F-41B7-9CD8-972C441EEE27Q35294224-53971AD4-A4AE-4BB5-8E4A-59ABAA0FE5AFQ35366716-1DD79C44-7B07-449E-AD6E-F85BD2E1E2ECQ37741221-7D23A2B0-650C-4EB5-B3B5-F4D170431BE3Q38290653-BE588B6C-FBC5-4CB8-89FA-387496D03133Q38917542-DF1E6279-9379-4833-8C8E-39C323E2A78EQ38977431-48B10341-53E9-497C-AE41-24FD82E4FA57Q38984366-2A8E0000-7E71-43F1-8F09-6D34766A27DEQ39716010-C4E0F91A-9D93-475F-9D11-52008E5C76D2Q39840981-7BB764D0-7436-46B1-95AC-3BB6553811E9Q39994251-0711356A-23EF-4A75-A566-482A8B3CC380Q39995755-5A772107-B00D-4A43-BE30-6CA2498BE730Q40002398-AF4F884B-559B-4EA1-B1A5-F91C12684AB2Q43192312-7D9D9847-9206-4CC6-B4A0-AA1D9654400FQ53545573-D0FC9612-123E-4AEA-95CC-26F3747160BBQ59489053-DE3F9661-3A9B-4195-8A1D-A7B971F15677Q59489056-CF6089DA-09B2-40D6-A6AD-64CF2E01AA3F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Hevia
@ast
David Hevia
@en
David Hevia
@es
David Hevia
@nl
type
label
David Hevia
@ast
David Hevia
@en
David Hevia
@es
David Hevia
@nl
prefLabel
David Hevia
@ast
David Hevia
@en
David Hevia
@es
David Hevia
@nl
P106
P21
P31
P496
0000-0002-1421-6262